Who Exports Trastuzumab from India — 179 Suppliers Behind a $77.2M Market
India's trastuzumab export market is supplied by 179 active exporters who collectively shipped $77.2M across 1,882 shipments. MYLAN LABORATORIES LIMITED leads with a 60.9% market share, followed by BIOCON BIOLOGICS INDIA LIMITED and ZYDUS LIFESCIENCES LIMITED. The top 5 suppliers together control 85.7% of total export value, reflecting a concentrated market structure.
Top Trastuzumab Exporters from India — Ranked by Export Value
MYLAN LABORATORIES LIMITED is the leading trastuzumab exporter from India, holding a 60.9% share of the $77.2M market across 1,882 shipments from 179 exporters. The top 5 suppliers — MYLAN LABORATORIES LIMITED, BIOCON BIOLOGICS INDIA LIMITED, ZYDUS LIFESCIENCES LIMITED, RELIANCE LIFE SCIENCES PRIVATE LIMITED, BIOCON BIOLOGICS LIMITED — collectively control 85.7% of total export value, indicating a highly concentrated market. Individual shares are: MYLAN LABORATORIES LIMITED (60.9%), BIOCON BIOLOGICS INDIA LIMITED (11.9%), ZYDUS LIFESCIENCES LIMITED (5.4%), RELIANCE LIFE SCIENCES PRIVATE LIMITED (5.0%), BIOCON BIOLOGICS LIMITED (2.5%).
Top Trastuzumab Exporters from India
Ranked by export value · 179 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | MYLAN LABORATORIES LIMITED TRASTUZUMAB LYOPHILIZED POWDER FOR INJECTION 440MG/VIAL.OGIVRI-150 TRASTUZUMAB 1S IRELAND (78022HERTRAZ 440MG (TRASTUZUMAB FOR INJECTION | $47.0M | 7 | 60.9% |
| 2 | BIOCON BIOLOGICS INDIA LIMITED OGIVRI 420 TRASTUZUMABTRASTUZUMAB LYOPHILIZED POWDER FOR INJECTION 440MG/VIAL.ZEDORA 440MG -TRASTUZUMAB FOR | $9.2M | 17 | 11.9% |
| 3 | ZYDUS LIFESCIENCES LIMITED MAMITRAWITHDIL.VIALSLMX | $4.2M | 8 | 5.4% |
| 4 | RELIANCE LIFE SCIENCES PRIVATE LIMITED CANMAB 440 MG/VIAL TRASTUZUMAB FOR INJECTION 440 MG/VIALCANMAB 440 MG/VIAL TRASTUZUMAB FOR INJEC | $3.9M | 15 | 5.0% |
| 5 | BIOCON BIOLOGICS LIMITED OGIVRI 420 TRASTUZUMABTRASTUZUMAB LYOPHILIZED POWDER FOR INJECTION 440MG/VIAL.ZEDORA 440MG -TRASTUZUMAB FOR | $1.9M | 1 | 2.5% |
| 6 | MEDWISE OVERSEAS PRIVATE LIMITED CANMAB 440-TRASTUZUMAB 440 MG INJECTIONTRASTUZUMAB 440MG INJECTIONTRASTUREL 44 | $1.1M | 3 | 1.5% |
| 7 | CHANDRA BHAGAT PHARMA LIMITED TRASTUZUMAB FOR INJECTION RDNATRASTUZUMAB FOR INJECTIONTRASTUZUMAB FOR INJECTION(RDNA | $970.4K | 1 | 1.3% |
| 8 | SAMEEKSHA PHARMACEUTICALS PRIVATE LIMITED CANMAB 440-TRASTUZUMAB 440 MG INJECTIONTRASTUZUMAB 440MG INJECTIONTRASTUREL 44 | $931.4K | 1 | 1.2% |
| 9 | NU HOSPITALS PRIVATE LIMITED | $673.7K | 1 | 0.9% |
| 10 | DR.REDDY'S LABORATORIES LTD HERTRAZ 440MG (TRASTUZUMAB FOR INJECTIONTRASTUZUMAB SOL INJ 150MG AMPOULE(HERVYCTRASTUZUMAB SOL INJ 150 MG | $610.3K | 4 | 0.8% |
| 11 | MYLAN PHARMACEUTICALS PRIVATE LIMITED TRASTUZUMAB LYOPHILIZED POWDER FOR INJECTION 440MG/VIAL.OGIVRI-150 TRASTUZUMAB 1S IRELAND (78022HERTRAZ 440MG (TRASTUZUMAB FOR INJECTION | $538.8K | 2 | 0.7% |
| 12 | CADILA HEALTHCARE LTD | $362.0K | 4 | 0.5% |
| 13 | PNT PHARMA | $303.1K | 1 | 0.4% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Trastuzumab exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| MYLAN LABORATORIES LIMITED | Warning Letter, December | Yes, as of March 202 | Not Listed | Not verified | Received FDA Warning Letter in December 2024; WHO conducted a for-cause inspecti |
| BIOCON BIOLOGICS INDIA LIMITED | Approved | Yes, date not specif | Yes, May 2020 | Not verified | Received EU GMP certification for multiple biosimilars manufacturing facilities |
| ZYDUS LIFESCIENCES LIMITED | Approved | Not Listed | Not Listed | Not verified | Received USFDA approval in October 2024 to manufacture enzalutamide tablets for |
| DR. REDDY'S LABORATORIES LTD | Approved | Not Listed | Not Listed | Not verified | Operates multiple FDA-inspected manufacturing facilities in India and the UK. |
| INTAS PHARMACEUTICALS LIMITED | Approved | Yes, date not specif | Yes, April 2007 | Not verified | Received EU GMP certification in April 2007; launched biosimilar Filgrastim in E |
| CADILA PHARMACEUTICALS LIMITED | Warning Letter, March 201 | Yes, date not specif | Not Listed | Not verified | Received FDA Warning Letter in March 2014 for manufacturing practice discrepanci |
TransData Nexus reviewed the regulatory standing of 6 leading Trastuzumab exporters from India. 4 hold US FDA facility approvals, 4 maintain WHO-GMP certification, and 2 are EU GMP compliant. 2 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Trastuzumab sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as "India's pharmaceutical capital," is a major hub for bulk drug manufacturing. The city hosts numerous pharmaceutical companies, including Natco Pharma, which specializes in active pharmaceutical ingredients (APIs) and finished dosage formulations. Hyderabad's infrastructure supports large-scale production, making it a pivotal center for the synthesis of complex biologics like Trastuzumab. The presence of specialized facilities, such as UPS's temperature-controlled cross-docking facility, further enhances the city's capability to handle sensitive pharmaceutical products.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Vadodara, in particular, is home to Alembic Pharmaceuticals, one of India's oldest pharmaceutical companies, established in 1907. The region's emphasis on formulations positions it as a key player in the production of finished pharmaceutical products, including biosimilars like Trastuzumab. The presence of numerous USFDA-certified facilities underscores the region's commitment to quality and compliance.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical products. Mumbai's strategic location and well-established port facilities facilitate the global distribution of pharmaceuticals, including Trastuzumab. The region's robust logistics infrastructure ensures efficient handling and shipment of pharmaceutical goods to international markets.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, primarily due to favorable tax incentives. This area attracts numerous pharmaceutical companies seeking cost-effective production solutions. While it may not be a primary hub for Trastuzumab production, the region's manufacturing capabilities contribute to the overall pharmaceutical supply chain.
5Sourcing Recommendations
- Evaluate Supplier Capabilities: Assess the technical expertise and production capacity of suppliers in Hyderabad for bulk drug manufacturing and in Ahmedabad-Vadodara for formulations to ensure they meet the specific requirements for Trastuzumab production.
- Ensure Regulatory Compliance: Verify that potential suppliers hold necessary certifications, such as USFDA approvals, to guarantee adherence to international quality standards.
- Leverage Export Infrastructure: Utilize the logistical advantages of the Mumbai-Thane-Raigad region to facilitate efficient global distribution of Trastuzumab.
- Consider Cost Efficiencies: Explore manufacturing options in the Baddi-Nalagarh region to potentially reduce production costs, keeping in mind the region's tax incentives and manufacturing capabilities.
By strategically engaging with these pharmaceutical clusters, TransData Nexus can optimize its supply chain for Trastuzumab, ensuring quality production and efficient distribution to meet global demand.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Trastuzumab exporters from India
Zydus Lifesciences Limited — Zydus acquires Agenus' biologics facilities, launches Zylidac Bio LLC
Zydus Lifesciences completed the acquisition of Agenus Inc.'s biologics manufacturing facilities in Emeryville and Berkeley, California. This acquisition led to the establishment of Zylidac Bio LLC, a U.S.-based subsidiary focused on biologics manufacturing. - IMPACT: This expansion enhances Zydus's manufacturing capabilities, potentially increasing Trastuzumab production capacity.
Impact: This expansion enhances Zydus's manufacturing capabilities, potentially increasing Trastuzumab production capacity.
Zydus Lifesciences Limited — Zydus enters biologics CDMO market with $125 million acquisitions
Zydus announced its entry into the global biologics contract development and manufacturing organization (CDMO) market by acquiring two U.S. biologics manufacturing facilities from Agenus Inc. for up to $125 million. - IMPACT: This strategic move positions Zydus to expand its biologics portfolio, including Trastuzumab, by leveraging enhanced manufacturing capabilities.
Impact: This strategic move positions Zydus to expand its biologics portfolio, including Trastuzumab, by leveraging enhanced manufacturing capabilities.
Zydus Lifesciences Limited — Zydus and Agenus close $141M collaboration to advance immunotherapies
Zydus and Agenus finalized a strategic collaboration to accelerate the development and commercialization of Agenus' immuno-oncology therapies, including botensilimab and balstilimab. The agreement includes exclusive rights for Zydus to develop and commercialize these therapies in India and Sri Lanka. - IMPACT: This partnership may lead to the development of new biologic therapies, potentially complementing Zydus's existing Trastuzumab offerings.
Impact: This partnership may lead to the development of new biologic therapies, potentially complementing Zydus's existing Trastuzumab offerings.
Common Questions — Trastuzumab Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which trastuzumab supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, MYLAN LABORATORIES LIMITED leads with 503 recorded shipments worth $47.0M. BIOCON BIOLOGICS INDIA LIMITED (39 shipments) and ZYDUS LIFESCIENCES LIMITED (68 shipments) are also established high-volume exporters.
Q How many trastuzumab manufacturers are there in India?
India has 179 active trastuzumab exporters with a combined export market of $77.2M across 1,882 shipments to 108 countries. The top 5 suppliers hold 85.7% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for trastuzumab from India?
Average FOB unit price: $260.46 per unit, ranging from $0.00 to $4825.10. Average shipment value: $41.0K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 179 verified Indian exporters of Trastuzumab ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 1,882 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 108 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,882 Verified Shipments
179 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists